Aegon is moving its legal seat to the US, rebranding as Transamerica. US sales are up 30%, and they are reviewing the UK business for potential sale. European insurers trade at a discount to US peers. By relocating the HQ and becoming a "US company" (Transamerica) while selling off non-core European assets (UK arm), the stock should re-rate to higher US valuation multiples. LONG. A regulatory arbitrage and restructuring play. Regulatory hurdles in the HQ move or failure to find a buyer for the UK unit.